{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:00:57Z","timestamp":1791381657906,"version":"4.3.3"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Entecavir (ETV) and tenofovir alafenamide (TAF) are two first\u2010line nucleos(t)ide analogs used for the treatment of chronic hepatitis B (CHB), each offering potent antiviral activity and a high barrier to resistance. We aimed to directly compare the effects of ETV and TAF on the quantitative reduction of hepatitis B surface antigen (HBsAg) levels in CHB patients. We screened 1342 consecutive CHB patients treated with ETV or TAF at our center between January 2007 and December 2021. In total, 493 patients were included in the final analysis (ETV,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009169; TAF,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009324). The primary endpoint was the difference in quantitative HBsAg reduction between the two groups at 12 and 24 months. Secondary endpoints included changes in the estimated glomerular filtration rate (eGFR), phosphorus, and low\u2010density lipoprotein (LDL)\u2010cholesterol levels. Although the absolute median HBsAg reduction was not significantly different between the TAF and ETV groups (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05), more patients in the TAF group achieved &gt;\u200910% quantitative HBsAg decline at 12 months (63.0%\n                    <jats:italic>vs<\/jats:italic>\n                    . 55.8%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009) and 24 months (81.7%\n                    <jats:italic>vs<\/jats:italic>\n                    . 65.1%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The TAF group demonstrated a stable median eGFR (mL\/min\/1.73\u2009m\u00b2) change compared to the ETV group (0.0 vs. \u22126.0,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003) at 24 months. The TAF group showed better preservation of serum phosphorus levels at 24 months (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003). The changes in LDL\u2010cholesterol levels were not significantly different between the two groups. In CHB patients, TAF showed a significantly higher proportion of quantitative HBsAg reduction and a superior renal safety profile than ETV, without significant differences in LDL\u2010cholesterol changes.\n                  <\/jats:p>","DOI":"10.1002\/jmv.70958","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:42:42Z","timestamp":1778244162000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Comparative Study of Entecavir and Tenofovir Alafenamide on Quantitative HBsAg Reduction in Patients With CHB"],"prefix":"10.1002","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-7218","authenticated-orcid":false,"given":"Jungnam","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Inha University Hospital, Inha University School of Medicine Incheon South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7449-2461","authenticated-orcid":false,"given":"Young\u2010Joo","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Inha University Hospital, Inha University School of Medicine Incheon South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.018"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00760-9"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.805625"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q833"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9061146"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.014"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.009"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2019.20.8.2239"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0780"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2019.1002"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2017.4963"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i25.7869"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1301120"},{"issue":"3","key":"e_1_2_10_16_1","article-title":"3\u2010year Treatment of Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China","author":"Hou J.","year":"2021","journal-title":"Journal of Clinical and Translational Hepatology"},{"key":"e_1_2_10_17_1","first-page":"72","volume-title":"Tenofovir aLafenamide Versus Tenofovir Disoproxil Fumarate: Is There A True Difference in Efficacy and Safety?","author":"Hill A.","year":"2018"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1185492"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262764"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12443"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70055"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(96)70070-7"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.172.2.2526349"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01584-4"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.02.007"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26041"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02048"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14040657"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030630"},{"issue":"3","key":"e_1_2_10_31_1","article-title":"Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which Is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta\u2010Analysis","author":"Ma X.","year":"2021","journal-title":"Journal of Clinical and Translational Hepatology"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25515"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01827-24"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.035"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312653"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/v17010044"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2021.0314"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0328"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae374"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02515-7"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2005.20.5.816"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3350\/kjhep.2009.15.2.140"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.70958","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.70958","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.70958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:48:18Z","timestamp":1791380898000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.70958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/jmv.70958"],"URL":"https:\/\/doi.org\/10.1002\/jmv.70958","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70958"}}